Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P591

Satisfaction with treatment amongst inflammatory bowel disease patients receiving subcutaneous biologic treatment and infused biologic treatment

Authors:

S. Wang*1, J. Piercy2, R. Jakubanis2, M. Skup1

1AbbVie Inc., North Chicago, Illinois, United States, 2Adelphi Real World, Manchester, United Kingdom

P592

Absenteeism and presenteeism amongst Crohn’s disease patients: results from a real-world cohort in Israel

Authors:

D. Schwartz*1, D. Greenberg2, E. Chernin2, H. Vardi2, M. Friger2, O. Sarid2, V. Slonim-Nevo2, S. Odes2

1Soroka UMC, Gastroenterology, Beer Sheva, Israel, 2Ben Gurion University, Beer Sheva, Israel

P593

Bone mineral density in a Spanish cohort of inflammatory bowel disease patients

Authors:

J. Miranda-Bautista*1, M. D. Perez-Valderas1, A. Caballero-Marcos1, A. Diaz-Redondo2, I. Marin-Jimenez1, L. Menchen1

1Hospital General Universitario ‘Gregorio Marañón’, Gastroenterology Unit, Madrid, Spain, 2Hospital General Universitario, Preventive medicine and Epidemiology Service, Madrid, Spain

P594

Infliximab for active ulcerative colitis: a prospective study on patients’ short-term response and long-term outcome.

Authors:

U. Nieminen*1, U. Turunen1, P. Arkkila1, T. Sipponen1, M. Färkkilä1, 2

1Helsinki University Hospital, Department of Gastroenterology, Helsinki, Finland, 2Helsinki University, Clinicum, Helsinki, Finland

P595

More than 10 years of experience of use methotrexate in Ulcerative colitis at Macarena Hospital, Sevilla, Spain

Authors:

M. F. Guerra Veloz*1, M. B. Maldonado Pérez1, A. Caunedo Álvarez1, L. Castro Laria1, J. L. Cotrina Lino2, F. Argüelles Arias1, A. Flores Cucho2, M. Romero Gómez2

1Unidad de Gestión Clínica de Aparato Digestivo Hospital Universitario Virgen Macarena, Seville, Spain, 2Hospital Universitario Virgen Macarena, Gastroenterology, Sevilla, Spain

P596

Analysis on adverse drug reactions of 103 inflammatory bowel disease patients using thalidomide

Authors:

P. Xiang*1, S. Ming-li2, G. xiang2, Z. Ming2

1The Sixth Affiliated Hospital, Sun Yan-sen University, Department of Gastroenterology, Guangzhou, China, 2The Sixth Affiliated Hospital, Sun Yan-sen University, Guangzhou, China

P597

Body composition: a biomarker of therapeutic outcome in patients with Crohn’s disease

Authors:

N. S. Ding*1, 2, G. Malietzis1, P. F. Lung1, W. Yip1, L. Penez1, T. Ganeshanathan1, S. M. Gabe1, 3, J. T. Jenkins4, 5, A. Hart1

1St Mark’s Hospital, IBD, London, United Kingdom, 2Imperial College London, Department of Surgery and Cancer, London, United Kingdom, 3Imperial College, Surgery, London, United Kingdom, 4St Mark’s Hospital, Department of IBD, Colorectal Surgery and Wolfson Unit of Endoscopy, London, United Kingdom, 5Imperial College, Surgery and Cancer, London, United Kingdom

P598

Dietetic intervention and nutritional status in adult patients with Crohn’s disease: preliminary results

Authors:

A. Dell’Era*1, V. F. Bernardo De Almeida2, L. Cioni3, A. Massari4, F. Muzio2

1UOC Gastroenterologia, Ospedale L. Sacco. Università degli Studi di Milano, Dipartimento di Scienze Biomediche e Cliniche, Milano, Italy, 2Servizio di Dietologia e Nutrizione Clinica, Ospedale L. Sacco, Milano, Milano, Italy, 3Servizio di Dietologia e Nutrizione Clinica, Ospedale L. Sacco, Milano, Italy, 4UOC Gastroenterologia, Ospedale L. Sacco, Milano, Milano, Italy

P599

Clinical practice and outcomes of iron isomaltoside administration in anaemic patients with Crohn’s disease and ulcerative colitis

Authors:

J. Stein*1, H. Hartmann2, A. Walper3

1Crohn’s and Colitis Centre, Gastroenterology, Frankfurt, Germany, 2Centre of Gastroenterology, Herne, Germany, 3MEDICE Arzneimittel Pütter GmbH, Medical Department, Iserlohn, Germany

P600

Safety and efficacy of infliximab biosimilar (Remsima©) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment

Authors:

M. F. Guerra Veloz*1, F. Argüelles Arias1, R. Perea Amarillo1, L. Castro Laria1, M. B. Maldonado Pérez1, A. Benítez Roldán1, V. Merino2, G. Ramirez2, A. Vilches Arenas3, A. Caunedo Álvarez1

1Unidad de Gestión Clínica de Aparato Digestivo Hospital Universitario Virgen Macarena, Seville, Spain, 2Unidad de Farmacia Hospital Universitario Virgen Macarena, Seville, Spain, 3Universidad de Sevilla, Medicina preventiva y salud pública, Seville, Spain

P601

The efficacy of GSK2586184, a novel selective Janus kinase1 inhibitor, in patients with moderate to severely active ulcerative colitis

Authors:

L. De Vries*1, 2, F. van Leeuwen-Hilbers2, C. Verseijden2, J. Duarte2, K. Hicks3, J. Patel3, V. Ludbrook3, W. De Jonge2, G. D’Haens1

1Academic Medical Centre (AMC), Gastroenterology & Hepatology, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands, 3GlaxoSmithKline, Immunoinflammation Therapy Area, Stevenage, United Kingdom

P602

Health-related quality of life improves during 1-year of postoperative prophylactic drug therapy after ileocecal intestinal resection in Crohn’s disease patients: results of the APPRECIA randomised trial

Authors:

C. Taxonera*1, A. Lopez-Sanroman2, M. I. Vera3, P. Nos4

1Hospital Clínico San Carlos, IBD Unit, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 3Hospital Puerta de Hierro, Gastroenterology, Madrid, Spain, 4Hospital La Fe, Gastroenterology, Valencia, Spain

P603

Response and remission rates with up to 3 years of vedolizumab treatment in patients with Crohn’s disease

Authors:

S. Vermeire*1, B.G. Feagan2, R. Mody3, A. Previtali4, B. Abhyankar4

1University Hospital Gasthuisberg, Gastroenterology, Leuven, Belgium, 2Robarts Research Institute, University of Western Ontario, Clinical Trials, London, ON, Canada, 3Takeda Development Centre Americas, Inc, Deerfield, Illinois, United States, 4Takeda Development Centre Europe Ltd, London, United Kingdom

P604

The negative role of the antibodies developed against the first anti-tumour necrosis factor (TNF) during the switch towards a second anti-TNF requires the use of an associated immunosuppressive agent

Authors:

C. Verot*1, E. Del tedesco2, J. M. Phelip2, L. Peyrin Biroulet3, X. Roblin2

1CHU Saint etienne, Saint etienne, France, 2CHU Saint Etienne, Saint Etienne, France, 3CHU Nancy, Nancy, France

P605

Effect of medication type on patients’ health-related quality of life in Crohn’s disease

Authors:

D. Schwartz*1, D. Greenberg2, E. Chernin2, O. Sarid2, V. Slonim-Nevo2, M. Friger2, H. Vardi2, S. Odes2

1Soroka UMC, Gastroenterology, Beer Sheva, Israel, 2Ben Gurion University, Beer Sheva, Israel

P606

Histological healing in ulcerative colitis with mesalazine and its prognostic role

Authors:

G. Frieri*, B. Galletti, M. Di Ruscio, R. Tittoni, A. Capannolo, G. Latella, L. Sollima, P. Leocata, S. Necozione, A. Viscido

University Of L’Aquila, L’Aquila, Italy

P607

Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease

Authors:

G. Bodini*1, L. Del Nero1, E. G. Giannini1, S. Tolone2, N. De Bortoli3, J. Anjali4, I. Baldissarro1, V. Savarino1, E. Savarino5

1University of Genoa, Internal medicine department, Genoa, Italy, 2Second University of Naples, Department of surgery, Naples, Italy, 3University of Pisa, Internal medicine department, gastroenterology unit, Pisa, Italy, 4Prometheus Laboratories, Department of Research and Development, San Diego, California, United States, 5University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Padua, Italy

P608

Systematic literature review of observational studies that assess the effectiveness of biologic drugs in the treatment of extra-intestinal manifestations in inflammatory bowel disease

Authors:

L. Peyrin-Biroulet1, G. Van Assche2, D. Gomez-Ulloa3, L. Garcia-Alvarez3, N. Lara3, C. Black4, S. Kachroo*4

1Lorraine University, Gastroenterology Department, Vandoeuvre, France, 2University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 3IMS Health, Real-World Evidence Solutions, Barcelona, Spain, 4Merck & Co, Inc, Centre for Observational and Real-World Evidence (CORE), Rahway, New Jersey, United States

P609

Efficacy and safety of adalimumab in paediatric patients with Crohn’s disease aged 10 years and younger: sub-analysis of IMAgINE 1

Authors:

F. Ruemmele*1, M. Dubinsky2, J. Hyams3, S. Eichner4, J.-F. Maa4, A. Lazar5, A. Robinson4, G. Alperovich6

1Universite Sorbonne Paris-Cite, Hospital Necker-Enfants Malades, Paris, France, 2Icahn School of Medicine at Mount Sinai, New York, New York, United States, 3Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 4AbbVie Inc, North Chicago, Illinois, United States, 5AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, 6AbbVie Inc, Madrid, Spain

P610

Factors associated with anti-tumour necrosis factor therapy failure in patients with Crohn’s disease: Does the type of drug have any influence?

Authors:

I. Baston*, M. Barreiro-de Acosta, D. De la Iglesia, R. Ferreiro, A. Lorenzo, J. E. Dominguez-Munoz

University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain